An Outcome Model Approach to Translating a Randomized Controlled Trial
  Results to a Target Population by Goldstein, Benjamin A. et al.
An Outcome Model Approach to Translating a Randomized Controlled Trial Results to a Target 
Population
Benjamin A. Goldstein, Matthew Phelan, Neha J. Pagidipati, Rury R. Holman, Michael J. Pencina 
Elizabeth A Stuart
Benjamin A. Goldstein
Department of Biostatistics and Bioinformatics
2424 Erwin Road,
Durham, NC  27705
ben.goldstein@duke.edu
ACKNOWLEDGMENTS
We thank the NAVIGATOR steering committee and investigators for access to the NAVIGATOR data
Affiliations: Department of Biostatistics & Bioinformatics, Duke University, Durham, NC (BAG, 
MJP); Center For Predictive Medicine, Duke Clinical Research Institute, Durham, NC (BAG, MP, 
NHJ); Department of Medicine, Duke University, Durham, NC (NHJ); Diabetes Trials Unit, Oxford 
Centre for Diabetes, Endocrinology, and Metabolism, University of Oxford, Oxford (RRH);  
Department of Biostatistics, Johns Hopkins University, Baltimore, MD (EAS)
Funding: This work was supported by National Institute of Diabetes and Digestive and Kidney 
Diseases (NIDDK) career development award K25 DK097279 (B.A.G.), US Department of Education 
Institute of Education Sciences Grant R305D150003 (EAS). The project described was supported by 
the National Center for Advancing Translational Sciences (NCATS), National Institutes of Health 
(NIH), through Grant Award Number UL1TR001117 at Duke University. The content is solely the 
responsibility of the authors and does not necessarily represent the official views of the NIH. 
NAVIGATOR was funded by Novartis.
An Outcome Model Approach to Translating a Randomized Controlled Trial Results to a Target 
Population
Abstract
Participants enrolled into randomized controlled trials (RCTs) often do not reflect real-world 
populations. Previous research in how best to translate RCT results to target populations has focused on
weighting RCT data to look like the target data. Simulation work, however, has suggested that an 
outcome model approach may be preferable. Here we describe such an approach using source data 
from the 2x2 factorial NAVIGATOR trial which evaluated the impact of valsartan and nateglinide on 
cardiovascular outcomes and new-onset diabetes in a “pre-diabetic” population. Our target data 
consisted of people with “pre-diabetes” serviced at our institution. We used Random Survival Forests to
develop separate outcome models for each of the 4 treatments, estimating the 5-year risk difference for 
progression to diabetes and estimated the treatment effect in our local patient populations, as well as 
sub-populations, and the results compared to the traditional weighting approach. Our models suggested 
that the treatment effect for valsartan in our patient population was the same as in the trial, whereas for 
nateglinide treatment effect was stronger than observed in the original trial. Our effect estimates were 
more efficient than the weighting approach. 
Introduction
Given good treatment compliance and minimal loss to follow-up, randomized controlled trials (RCTs) 
provide an internally valid estimate of a sample average treatment effect (SATE) for the evaluated 
intervention. If the RCT patient cohort is representative of the larger patient population, one can 
typically extrapolate the SATE to the larger patient population, to give a population average treatment 
effect (PATE). Unfortunately, for both intentional and unintentional reasons, RCTs rarely fully reflect 
general patient populations(1–3). This may be because it is advantageous to recruit patients that are not 
taking other medications, have fewer comorbidities or who are more likely to experience the primary 
outcome of interest. If the effectiveness of the intervention varies based on factors that differ between 
the RCT and general population, i.e. there are effect modifications, then the PATE will not equal the 
SATE and the inference derived from an RCT may not be valid in different clinical populations.
For these reasons, there has been increasing interest within the causal inference literature in 
developing methods to translate RCT results to target populations, estimating what is referred to as the 
target average treatment effect (TATE)  (4–11). The majority of this work has aimed to account for the 
selection process into the trial by developing weights using a model of the probability of a person being
as part of the RCT versus the target population. These weights are then used to make the RCT 
population look like the target population – typically a larger national population. These approaches 
have good theoretical properties and have been developed to incorporate a double-robust 
framework(12). 
The weighting approach, however, has two potential drawbacks. First, every time results need 
to be translated to a new patient population, a new set of weights needs to be estimated.  In most of the 
literature the target population is taken as the general US population, e.g. defined by NHANES, but in 
our work we often consider the target population to be patients served by the health system at a local 
institution. Amid changes to patient reimbursement, medical centers are becoming financially 
responsible for managing the health of their patient population (13).In order to manage a population 
cost effectively, health systems need to be able to reliably translate RCT results to real world 
populations. Since each health system has different patient characteristics, any application to any new 
health system, or population subset of interest, would require an estimation of a new set of weights. 
Second, the ability to estimate these weights accurately is partially driven by the sample size of the 
target population. When generalizing to a single, large population, this is not a concern. However, there
may be situations where the local population is small, e.g. a single hospital or clinic. Accordingly,  
methods that are not dependent on the target sample size are desirable.
With these weighting approach limitations in mind, we have considered an outcome model 
approach to generalizing RCT results. The reasoning behind the outcome model approach, described in 
detail below, is that prediction models are built among those receiving or not receiving the intervention 
and then the target population is “passed” through each model to produce potential intervention 
outcomes for each individual in the target population. This methodology allows individual treatment 
effects (ITEs) to be estimated which can be averaged to calculate the TATE. This approach resolves the 
two challenges itemized above: the model only needs to be estimated once before applying to any 
target population, and that target population can be as small as desired. Kern et al.(11) used simulation 
to compare weighting, doubly robust, and outcome model approaches and found that the outcome 
model approach had the best performance. 
In this paper we build off Kern ozan aet al. to further develop a machine learning approach to 
estimate the TATE. To do so we incorporate the causal Random Forests (RF) framework (14). Our 
intent is not to argue for supremacy of the outcomes model approach over the weighting approach but 
moreso to illustrate how to implement it. We used source data from the 2x2 factorial-design 
NAVIGATOR (Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research) 
international trial which evaluated the impact of valsartan and nateglinide on cardiovascular outcomes 
and new-onset diabetes in 9,306 “pre-diabetic” individuals. We then applied our results to “pre-
diabetic” individuals found in our institution’s electronic health record (EHR) system to estimate the 
TATE for this local patient population.
METHODS
We first describe the general analytic approach. Next we describe the data used for analysis, both 
source and target. Finally we outline our evaluation.
Analytic Approach
Figure 1 presents a schematic oozan af the analytic approach. Our approach builds off of work 
by Lu et al. (14) on causal RF. RFs (15) are an extension of Categorization and Regression Trees 
(CART) that combines multiple trees via a process called bagging (bootstrap aggregation) to create a 
more robust predictor. RF is a highly effective prediction model that has been used in a range of clinical
studies, and is increasingly being used for causal inference (16). Lu et al. describe seven different 
approaches for estimating the ITE with RF. The approach we adopt here is referred to as 
Counterfactual RF (cRF). In cRF one identifies an outcome Y, treatments T Є {A,B} and covariates W. 
One then splits the data between those that received the treatment A, and those that received treatment 
B. Using the covariates W, one builds a model for the outcome separately for each treatment group. 
This generates two models, m: 
m^a≡ E (Y∨W s , T=A ) ;m^B ≡ E (Y ∨W s ,T=B )
To estimate the ITE for a new observation, e.g. someone from a target sample, one passes the 
observation through each model, generating predicted values under each condition:
Y^ i , A=mA (W T , A ); Y^ i , B=mB (W T , B )
We define the ITE as:
τ^ i=Y^ i , A −Y^ i , B
We then average over all τ^ i  to get the TATE. We note that this is a modification of the approach by 
Lu et al., who utilize the out-of-bag sample of RF to estimate the ITE within the developmental data. 
The rationale behind the approach is that by generating two separate models, any heterogeneity is 
implicitly modeled, allowing the outcomes under each condition to freely differ. Moreover, as we 
illustrate in our application, when there are multiple potential treatments, multiple contrasts is a 
straightforward calculation of the relevant comparison. An implicit assumption in this approach is that 
the potential outcomes for an individual are independent of one another, given the observed covariates. 
If there are unobserved effect modifiers any estimation of the TATE will produce biased results.
To generate standard errors for the TATE we need to determine the source of variability. The 
above procedure is comprised of two set of data: a RCT source sample and a local target patient 
population. We use the RCT data to estimate m^() . We consider this sample random and 
consequently m^()  random. Conversely, we consider the target population fixed, and the TATE, once
m^() is estimated, fixed. Therefore, the primary source of variability comes from the estimation of
m^() . To estimate this variability, we follow the approach of Lu et al. and generate bootstrap samples
of the data, refitting the RF models on each bootstrap and reestimating the individual ITEs and 
combined TATE. We use the estimated standard errors from the bootstrap distribution along with a 
normal approximation to generate a confidence interval. By generating standard errors in this way, the 
variability is not a function of the target sample size, only the source sample size.
Aligning the Input Data
An implicit component of this process is that the same W exist within both the source and target
samples. Typically, RCTs have dozens of baseline covariates that are well defined and adjudicated. 
Conversely, EHR data typically have hundreds of covariate values that are not necessarily available for 
all patients. Moreover, similar measures are not necessarily equally defined. For example, within an 
RCT a glucose test result may be measured via fasting glucose while an EHR may contain a mixture of 
fasting and random glucose tests. As such many of the same data elements may not exists in both data 
sources(17).  Therefore, care is necessary to ensure that there is alignment between the input variables. 
Particularly, it may be necessary to remove W that are not present in both data sources, as we describe 
below.
Data
Source Data. For our analysis we used data from the NAVIGATOR trial(18). NAVIGATOR was a 2x2 
factorial-design trial comparing two medications, valsartan and nateglinide, in people with “pre-
diabetes. These medications were compared against each other, against a placebo, and in combination. 
In total there were six comparisons. Published results found that Valsartan(19) was effective in 
reducing the incidence of diabetes while Nateglinide(20) was not.
In the trial, of the 9,306 participants, 2315, 2329, 2316, and 2346 were allocated to receive 
valsartan monotherapy, nateglinide monotherapy, valsartan-nateglinide combination therapy, and 
placebo, respectively. Inclusion criteria included impaired glucose tolerance (defined by glucose levels 
≥140 mg/dL (7.8 mmol/L) but <200 mg/dL (<11.1 mmol/L) 2 hours after 75g glucose intake), plus one 
or more cardiovascular risk factors including: family history of premature coronary heart disease, 
current smoker, hypertension, reduced high-density lipoprotein, elevated low-density lipoprotein, left 
ventricular hypertrophy, microalbuminuria. Exclusion criteria included the use of an ACE inhibitor or 
ARB for the treatment of hypertension or the use of an antidiabetic medication in the last 5 years. 
Baseline information was available across 46 clinical and demographic factors. Median follow-up was 
6.5 years.  We considered our primary end-point to be the risk difference for new-onset diabetes at 5 
years. 
Target Data. Our motivation for this work was to translate trial results to our institution’s patient 
population. Duke University Health System (DUHS) consists of three hospitals and a network of 
outpatient clinics, along with linkable data from a federally qualified health clinic, serving an under-
served population. As the only provider in Durham County, it is estimated that 85% of Durham County 
residents receive their primary care through DUHS(21).
To identify the local, target population we abstracted data from our institution’s EHR system 
(See Figure 2 for Consort Diagram). To identify pre-diabetics we selected patients with a glycated 
hemoglobin A1C between 5.7% and 6.4%, with the condition that they never had a previous result 
greater or equal to 6.5%. We considered the first encounter with an HgB A1C in this range as the index 
date. We included patients seen between 2010 – 2016. To ensure that DUHS was a patient’s medical 
home, we limited our analysis to individuals that lived in Durham County and had at least 2 encounters 
in the 2 years prior to the index date. 
In total we were able to identify 35 (76%) of the NAVIGATOR baseline characteristics within 
our EHR. This included demographic variables, vital signs, comorbidities, labs and medications.  For 
variables with multiple measurements (e.g., systolic blood pressure) we used the median of all 
measurements taken in the year prior to the index date. Variables that we were not able to confidently 
identify within the EHR included: current smoking status (though smoking history was available), 
familial diabetes history, waist circumference, plasma glucose 2 hr after glucose load, and ratio of 
urinary albumin to creatinine. Since the occurrence of fasting-glucose was rare within our EHR, we 
used glycated hemoglobin A1C as an indicator of a pre-diabetic patient. 
Analytic Approach
Preliminary Analyses.  We compared the patient characteristics between the NAVIGATOR and DUHS 
patients using standardized mean differences (SMD). We consider an SMD greater 0.1 to indicate a  
meaningful difference between the two populations(22).
Primary Analyses. We performed a series of analyses considering all six components of the 2x2 
factorial design, but focusing on the valsartan and nataglinide comparisons versus placebo. We first 
estimated the SATE in the original NAVIGATOR RCT, estimating the risk difference at 5 years for 
each of the six comparisons. We performed this analysis as an intent-to-treat analysis fitting a Kaplan 
-Meier estimator and then taking the effect estimate at 5-years. Next, we used the NAVIGATOR data to
build a cRF for the valsartan, nataglinide, combination therapy and placebo cohorts. Specifically, we 
used Random Survival Forests(23) to predict risk of diabetes at 5-years for each arm. We fit 500 trees 
within each forest. Using these forests we considered the six potential contrasts. We first used the 
forests to estimate the treatment effect among the NAVIGATOR sample. We used the out-of-bag 
sample from each bootstrap iteration to estimate the probability of diabetes, and then, for each contrast 
of interest, calculated the ITE and TATE as described above. We considered this analysis a test of 
internal validity of the method, i.e. this analysis should replicate the estimate in the first analysis. Third,
we applied the pre-diabetic individuals in the DUHS population to the cRF to estimate the target 
sample risk difference. We estimated the risk difference as above. For each analysis we performed 1000
bootstraps to estimate standard errors and calculate 95% confidence intervals.
As a secondary analysis, we considered the TATE across different sub-populations. Specifically,
we considered differences based on: Sex, Race, and history of CVD.
Sensitivity Analysis. We performed two sensitivity analyses. First we limited the cohort to those 
individuals who would have met inclusion criteria for the original Navigator trial. Specifically, we 
required individuals to have at least one cardiovascular risk factor (history of smoking, hypertension, 
left ventricular hypertrophy, microalbumineria, reduced HDL [HDL < 40] or elevated LDL [LDL > 
160]), excluded anyone currently on an ACE or ARB and limited the cohort to 2010 – 2011. Second, 
we compared our analysis to the more traditional weighting approach. While different proposals have 
been made, we followed the approach outlined in (5). We used the baseline characteristics to estimate 
selection weights. We note the authors mention using subject matter knowledge to decide which 
characteristics to include. Given our sample size we used all available baseline variables, using a RF 
estimated probability weights. We then performed a weighted regression to estimate the risk difference,
and 1000 bootstraps to generate standard errors.
All analyses were performed in R 3.4.2. The RF model was estimated using the package 
randomSurvivalForests (24). This work was approved by our institution’s IRB.
RESULTS
We identified 20,068 pre-diabetic patients in the DUHS EHR system. Table 1 shows the 
comparison of the source RCT and target EHR populations. In general, the RCT population was sicker 
with higher systolic blood pressure, more comorbidities, and more medication prescriptions. Of note 
the two groups had comparable HgbA1c, an important marker for pre-diabetes.
Assessment of Valsartan & Nateglinide
We first assessed the independent effect of Valsartan versus placebo (Table 2). Using the 
original NAVIGATOR data we estimated a significant effect for the risk difference at 5-years (-0.056, 
95% CI: -0.085, -0.027), as in the originally published RCT. We were able to replicate this result when 
re-translating the cRF result back to the NAVIGATOR patient population (-0.051, 95% CI: -0.073, 
-0.028). Finally, when generalizing the effect to the Duke EHR defined population we get a similar, if 
not slightly stronger, effect estimate (-0.069, 95% CI: -0.119, -0.016).
We next assessed the independent effect of Nateglinide vs placebo. The original RCT reported a
null effect, which we were able to confirm using the source data (0.009 95% CI: -0.021, 0.039), as well
as through our internal validation of generalizing back to the RCT sample (-0.004 95%CI: -0.02, 
0.013). However, when translating the effect to Duke EHR defined population we get a stronger, if not 
statistically significant effect (-0.030 95% CI: -0.077, 0.016).
We also assessed the additional comparisons of the two active drugs with each other as well as 
combination therapy versus mono-therapy (Table 2). Of note, the original RCT found valsartan to be 
superior to nateglinide, which was confirmed in our re-analysis of the risk difference (-0.065, 95% CI: 
-0.094, -0.036). However when translating the effect to the Duke patient population, this effect is 
attenuated and is no longer statistically significant (-0.039, 95% CI: -0.085, 0.010), likely due to the 
larger effect size of nateglinide versus placebo. 
Subgroup Analyses
To illustrate the flexibility of the approach we examined the treatment effect in different sub-
populations of our target populations (Figure 3). In general, we found similar treatment effects among 
the different sub-populations. One notable exception was the treatment effect for nateglinide among 
Caucasians (-0.016, 95% CI: -0.051, 0.021) versus African Americans (-0.041 95% CI: -0.095, 0.012). 
Since there is a greater proportion of African Americans in the Duke patient population, compared to 
the NAVIGATOR sample, it is possible that this difference is what accounts for the overall different 
observed treatment effect for nateglinide.
Sensitivity Analysis
As a sensitivity analysis we restricted the cohort to those patients that could have met inclusion 
criteria for the original NAVIGATOR study (n = 3,952). The results were very similar to the full sample
results (Table 2). We next compared our findings to the more commonly applied sample weighting 
approach (Table 2). We found translated treatment effects of –0.054 (95% CI: -0.131, 0.021) and 0.008 
(-0.080, 0.089), for the valsartan vs placebo and nateglinide vs placebo comparisons respectively. 
While these effects are more similar to the original trial estimates, we note the particularly large 
standard-errors. The average standard-error for the outcome model were 0.02 versus 0.04 for the 
weighting approach.
DISCUSSION
We have illustrated an approach to translate a treatment effect from an RCT to a target 
population. In contrast to much of the literature in this area, which focuses on weighting the source 
data, we focus on developing an outcome model. This allows us to treat this as two step process, 
decoupling the source and target populations results in two key advantages. First, we are able to easily 
translate the result to any population or sub-population of interest using the model fit in the trial 
sample. We do not need to reestimate weights for each new target. Second, the ability to translate the 
results is not dependent on the sample size of the target population. 
In comparing the RCT sample to our local patient population, we noted that the RCT population
was generally sicker, with higher blood pressure, more comorbidities and more medications. This 
confirms previous literature that has shown that RCT samples are generally sicker than the general 
population(3). Interestingly, other work has suggested that EHR based populations are sicker than 
general clinical populations (25) suggesting that these differences may be an underestimate, and in fact 
differences may be even more extreme when compared to a general patient population.
Upon translating the RCT results to our local population we were able to find a similar, 
significant, TATE as the RCT based SATE for the valsartan vs placebo comparison. However, while the
SATE for the nateglinide vs placebo comparison showed no treatment benefit, the TATE did suggest 
some treatment effect – though not statistically significant. This result followed through when we 
considered some of the comparisons based on combination therapy. For example, the SATE for 
valsartann + nateglinide versus just nataglinide showed a significant treatment effect, while the TATE 
did not. 
An important feature of the outcome model approach is that the estimation of the outcome 
model is decoupled from the translation step. This means that an RCT can generate an outcome model 
without knowledge of the target population. All that is required is to be able to map the covariates in 
the target population back to the trial data – admittedly not always an easy task. This feature is what 
makes translation to additional sub-populations so efficient. When we applied our analysis to different 
sub-populations we found similar treatment effects within the exception of a heterogeneous racial effect
among those taking nateglinide. While it is typical to use trial data to assess treatment heterogeneity, 
we note that the original trial did not report a significant effect for racial heterogeneity (p = 0.82). This 
suggests that this may effect differences is not due solely to racial differences, but higher-order 
interaction effects. Overall, it is likely that these differences is what accounted for the difference in the 
SATE and TATE estimates.
Embedded in our analysis is the ability to check the internal validity of the outcome model. By 
leveraging the out-of-bag samples from the RF bootstrap iterations, we re-applied the outcome model 
to the RCT population. We were able to find similar effect estimates as the original trial, suggesting that
our approach is relatively stable. We should suggest that this should be a standard first step when 
applying such an analysis.
In addition to the computational efficiency of using the out-of-bag sample to validate the 
approach, there are other advantages to using RF to derive the outcome model. Since RF is based on 
trees, it is more robust to outlying values, and consequently extrapolation, from the target sample. 
Unlike linear models, trees do not extrapolate predictions when the observed covariates extend beyond 
the support of the source data. This is an important consideration because, as we noted, there were 
meaningful differences between the RCT and DUHS samples. In general the question of how to 
estimate the TATE when the source and target samples differ is worthy of more future research.
Finally, we note that when we compared our outcome model approach to the more typical 
weighting approach we found our effect estimates to have meaningfully smaller standard errors. This 
empirical finding confirms the simulation results of Kern et al.(11) One intuition for why this is the 
case is that the estimation of sample weights relies on both the target and source sample while the 
proposed approach only relies on the source data. Moreover, RF is a relatively stable predictor that has 
low predictive variance.(26)
There are some notable limitations in our analysis and analytic approach. First, these are the 
results of one analysis. This approach should be tried with different source and target samples to note 
any additional potential complications as well as additional simulation work to better understand when 
and how the methods work. It would be interesting to compare the TATE different in different clinical 
populations to assess how much potential clinical heterogeneity exists. Moreover in our analysis we 
had a relatively large RCT from which to work. It is worth investigating what is the minimum size 
under which such an approach will still provide valid and efficient estimates. More generally, 
additional work in this field should consider the effects of translating trial results outside the support of 
the trial data. Finally, a key challenge in this area is what to do when variables are not directly 
comparable between the source and target data. This is an especially important concern with EHR data 
where clinical factors are measured in different ways. Hong et al.(6) has done some work in this area 
showing how multiple imputation can be used for missing individual values, but more work is needed 
to understand how best to handle, observed, but unmappable, covariates.
In this analysis, we illustrate a means to translate a RCT result to a target population. By using 
an outcome model approach, we are able to efficiently translate the results to target populations of 
different sizes.
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Table 1 - Differences in Baseline Characteristics of Target and Source Populations
Characteristic
Local Pre-Diabetic
Population
(N=20,068)
NAVIGATOR
(N=9,306)
Standardized
Mean Difference
Age (yrs) (Median, Percentiles) 52.6 (41.6- 63.2) 63.0 (58.0- 69.0) -0.907
Female sex 12601 (62.8%) 4711 (50.6%) 0.247
Race
Asian 656 (3.3%) 613 (6.6%) -0.154
Black 9927 (49.5%) 236 (2.5%) 1.266
Other 2245 (11.2%) 723 (7.8%) 0.117
White 7240 (36.1%) 7734 (83.1%) -1.092
Weight (kgs) (Median, Percentiles) 87.8 (74.2- 104) 82.0 (71.5- 93.5) 0.148
BMI (Median, Percentiles) 31.4 (27.1- 37.1) 29.7 (26.8- 33.3) 0.046
SBP (mmHg) (Median, Percentiles) 128 (119- 138) 140 (128- 150) -0.588
DBP (mmHg) (Median, Percentiles) 78.3 (72.0- 84.4) 84.0 (78.0- 90.0) -0.57
Cardiovascular Risk Factors 
Any 16502 (82.2%) 8921 (95.9%) -0.447
Smoking History 7497 (37.4%) 1025 (11.0%) 0.647
Hypertension 12016 (59.9%) 7216 (77.5%) -0.388
Left Ventricular Hypertrophy 968 (4.8%) 268 (2.9%) 0.101
Microalbuminuria 244 (1.2%) 114 (1.2%) -0.001
History of cardiovascular disease 
Any 2651 (13.2%) 2745 (29.5%) -0.406
Myocardial Infarction 504 (2.5%) 1103 (11.9%) -0.368
Angina 441 (2.2%) 1561 (16.8%) -0.514
Percutaneous Coronary Intervention 777 (3.9%) 622 (6.7%) -0.126
Coronary-Artery Bypass Grafting 20 (0.1%) 521 (5.6%) -0.335
Intermittent Claudification 526 (2.6%) 98 (1.1%) 0.117
Lower-limb angioplasty 16 (0.1%) 110 (1.2%) -0.14
Nontraumatic leg or foot amputation 14 (0.1%) 7 (0.1%) -0.002
Stroke 1506 (7.5%) 374 (4.0%) 0.15
Labs at time of index date 
Fasting Glucose mmol/L (Median, Percentiles) 5.4 (5.0- 5.9) 6.1 (5.7- 6.4) -0.633
Table 1 - Differences in Baseline Characteristics of Target and Source Populations
Characteristic
Local Pre-Diabetic
Population
(N=20,068)
NAVIGATOR
(N=9,306)
Standardized
Mean Difference
A1C (Median, Percentiles) 5.9 (5.8- 6.1) 5.8 (5.5- 6.1) 0.393
Total Cholesterol (Median, Percentiles) 187 (161- 214) 207 (181- 236) -0.503
HDL-C (Median, Percentiles) 46 (38- 55) 48 (40- 57) -0.132
LDL-C (Median, Percentiles) 113 (91- 137) 124 (100- 150) -0.312
Creatinine mg/dL(Median, Percentiles) 0.9 (0.8- 1.0) 0.8 (0.7- 1.0) 0.184
Estimated GFR (Median, Percentiles) 90 (74- 106) 80 (69- 91) 0.194
eGFR<60 1842 (10.8%) 1025 (11.1%) -0.061
Medications at time of index date 
ACE inhibitor 3346 (16.7%) 676 (7.3%) 0.293
Angiotensin-receptor blocker 1239 (6.2%) 30 (0.3%) 0.335
Alpha-blocker 633 (3.2%) 577 (6.2%) -0.145
Aspirin or other antiplatelet drug 5500 (27.4%) 3425 (36.8%) -0.202
Beta-blocker 3376 (16.8%) 3666 (39.4%) -0.518
Calcium-channel blocker 3354 (16.7%) 3012 (32.4%) -0.37
Diuretic 4895 (24.4%) 2960 (31.8%) -0.166
Lipid-modulating drug 6496 (32.4%) 3577 (38.4%) -0.127
Any Medication 11450 (57.1%) 7794 (83.8%) -0.612
Table 2: Risk difference at 5-years across different treatment comparisons and populations
Valsartan  VS
Placebo
Nateglinide  VS
Placebo
Valsartan  VS
Nateglinide
Valsartan +
Nateglinide VS
Placebo
Valsartan +
Nateglinide VS
Valsartan
Valsartan +
Nateglinide VS
Nateglinide
Sample Average 
Treatment Effect in 
NAVIGATOR Trial
-0.056 
(-0.085 ,  -0.027)
0.009 
(-0.021 ,  0.039)
-0.065 
(-0.094 ,  -0.036)
-0.036 
(-0.065 ,  -0.007)
0.02 
(-0.009 ,  0.048)
-0.045 
(-0.075 ,  -0.016)
Re-Translation to 
NAVIGATOR 
Sample*
-0.051 
(0.073 ,  -0.028)
-0.004 
(-0.02 ,  0.013)
-0.047 
(-0.064 ,  -0.032)
-0.047 
(-0.063 ,  -0.031)
0.004
 (-0.012 ,  0.021)
-0.043
 (-0.067 ,  -0.021)
Translation to local 
pre-diabetic 
population*
-0.069
 (-0.119 ,  -0.016)
-0.030 
( -0.077 ,  0.016)
-0.039
 ( -0.085 ,  0.01)
-0.043 
(-0.086 ,  0.004)
0.025
 (-0.025 ,  0.072)
-0.013 
(-0.056 ,  0.03)
Translation to local 
pre-diabetic 
population eligible 
for NAVIGATOR*
-0.069
 (-0.119 ,  -0.015)
-0.031 
(-0.082 ,  0.017)
-0.038 
(-0.084 ,  0.012)
-0.036 
(-0.082 ,  0.014)
0.034
 (-0.019 ,  0.083)
-0.004 
(-0.049 ,  0.042)
Translation to local 
pre-diabetic 
population using 
weighting to local 
population
-0.063
 (-0.147 ,  0.017)
0.003
 (-0.091 ,  0.094)
-0.06
 (-0.152 ,  0.022)
-0.03 
(-0.121 ,  0.067)
0.031 
(-0.056 ,  0.111)
-0.03 
(-0.116 ,  0.06)
* Each of these methods used the counter-factual random forests aproach for estimation
Figure 1: Flow diagram for implementation of outcome approach. We start with RCT Source data. 
Divide the data between those receiving the treatments of interest. Estimate separate outcome models. 
Identify the target data. Predict individual outcomes under each model. Calculate the individual 
treatment effect (ITE) and average to obtain the target averaged treatment effect (TATE).
Figure 2: Consort diagram for identification of EHR based target cohort.
Figure 3: Effect estimates for different patient subgroups. 
